Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status.
周日，安进公司（纳斯达克股票代码：AMGN）和阿斯利康公司（纳斯达克股票代码：AZN）公布了Tezspire（tezepelumab-ekko）针对严重慢性阻塞性肺病（COPD）的2a期COURSE试验结果，无论肺气肿、慢性支气管炎或吸烟状况如何，其基线血液嗜酸性粒细胞计数（BEC）都具有广泛的基线血液嗜酸粒细胞计数（BEC）。
The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant (p[1-sided]=0.1042).
主要结果表明，与第52周的安慰剂相比，使用Tezspire治疗使中度或重度慢性阻塞性肺病发作的年发作率降低了17％，这在统计学上并不显著（p [单面] =0.1042）。
The proof-of-concept study showed that, in patients with BEC ≥150 cells/μL, tezepelumab led to a nominally significant reduction of 37% in the rate of moderate or severe exacerbations compared to placebo.
概念验证研究表明，在BEC≥150细胞/μL的患者中，与安慰剂相比，tezepelumab使中度或重度发作率名义上显著降低了37％。
Among patients with BEC ≥300 cells/μL, tezepelumab led to a numerical reduction of 46% in the rate of moderate or severe exacerbations.
在BEC≥300个细胞/μL的患者中，替泽匹鲁单抗使中度或重度发作率的数字降低了46％。
A subgroup analysis of the COURSE trial also showed that treatment with tezepelumab resulted in numerical improvements in lung function as measured by forced expiratory volume (FEV1) (improvement of 63 mL and 146 mL in BEC ≥150 and ≥300 cells/μL respectively, compared to placebo) and in quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) score (reduction of 4.2 points and 9.5 points in BEC ≥150 and ≥300 cells/μL respectively).
对COURSE试验的亚组分析还显示，使用替泽匹鲁单抗治疗可以改善肺功能（以强制呼气量（FEV1）来衡量（与安慰剂相比，BEC ≥150和≥300个细胞/μL分别改善了63 mL和146 mL），以及根据圣乔治呼吸问卷（SGRQ）得分（降低4.2分和9.5分）来衡量的生活质量分别为 ≥150 和 ≥300 个细胞/μL）。
The safety and tolerability profile for tezepelumab was consistent with its approved severe asthma indication.
tezepelumab的安全性和耐受性特征与其批准的严重哮喘适应症一致。
Price Action: AMGN shares are up 0.40% at $313.74, and AZN shares are up 0.18% at $77.04 at last check Monday.
价格走势：周一最后一次查看时，AMGN股价上涨0.40％，至313.74美元，AZN股价上涨0.18％，至77.04美元。
Photo by Minerva Studio via Shutterstock
照片由 Minerva Studio 通过 Shutterstock 拍摄